Alumis
Market cap $628M 129.8M shares (vendor count, Nov 18, 2026) × $4.84 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-19
- Envudeucitinib psoriasis NDA filingby the end of 2026Envudeucitinib psoriasis NDA filing, by the end of 2026, notable
- Envudeucitinib psoriasis Ph2 readout4Q 2026Envudeucitinib psoriasis Ph2 readout, 4Q 2026, notable
- Zasocitinib Takeda FDA decision1Q 2027Zasocitinib Takeda FDA decision, 1Q 2027, material
- Envudeucitinib lupus corporate update2027Envudeucitinib lupus corporate update, 2027, routine
- A-005 Ph2 start2027A-005 Ph2 start, 2027, routine
- Next clinical candidate undisclosed Ph12027Next clinical candidate undisclosed Ph1, 2027, routine
- Envudeucitinib psoriasis PDUFA date~Feb 2027Envudeucitinib psoriasis PDUFA date, ~Feb 2027, major
- Envudeucitinib psoriasis PDUFA date~About late 2027 (estimate)Envudeucitinib psoriasis PDUFA date, ~About late 2027 (estimate), material
- Alumis corporate financing4Q 2027Alumis corporate financing, 4Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
envudeucitinib
ESK-001A-005
Discontinued (1)
- lonigutamab — Thyroid Eye Disease · strategic deprioritization; exploring strategic alternatives for asset
Capital (as filed)
- Cash
- $57.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$79.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $431M cash, runway into the fourth quarter of 2027 per the deep dive of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (1)
- 2026-11-13 Alumis (ALMS) - Scientific Deep Dive for Envudeucitinib, A-005 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (1 call)
Every verdict Biotech Distilled has published on Alumis, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-13 Watch Alumis (ALMS) - Scientific Deep Dive for Envudeucitinib, A-005 and Pipeline Products Envu is an approvable, royalty-free, top-tier oral psoriasis drug at a reasonable EV, but the going-concern qualification, near-certain dilutive raise of 30-40%, fourth-to-market BID positioning, and failed lupus trial make it not cheap enough to own the financing.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseAlumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updatesvia aggregator
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1
- Nov 12, 202610-QQuarterly report
- Sep 1, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Aug 10, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Jul 2, 2026SCHEDULE 13D/A13D amendment
- Jul 2, 20268-KCurrent report: shareholder vote
- Jun 29, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- May 18, 2026DEFA14AProxy soliciting material
- May 18, 2026DEF 14AProxy statement
- May 14, 20268-KCurrent report: results of operations · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 3, 2026SCHEDULE 13D/A13D amendment
- Mar 30, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Mar 19, 2026S-3ASRAutomatic shelf registration
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 18, 2026ARSAnnual report to shareholders
- Apr 7, 2026SCHEDULE 13GPassive >5% holder (13G)